Biocon Biologics Acquired R&D Footprint From Pfizer Healthcare India
Biocon Ltd has announced Biocon Biologics has acquired R&D capital assets for a 60,000 sq. ft state of the art bench to pilot scale Biologics research facility at TICEL Bio Park in Chennai, Tamil Nadu. The high-end integrated R&D facility in chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide.
The investment will allow us to fast-forward development of our biosimilars from lab to pilot scale. The facility will house an early stage research and innovation center including a pilot scale R&D Unit, well-equipped with cell line development, drug substance process development from bench scale to 400 litre scale bioreactors, drug product formulation laboratories and analytical R&D laboratories. The facility is expected to be operational in a few months post qualification and will house over 250 scientists who will have access to state of the art R&D labs equipped with over 500 high- end process and analytical instrumentation. The new facility provides Biocon Biologics a significant time advantage in comparison to setting up a greenfield R&D project and will accelerate the global development of our biosimilars portfolio